BioHarvest Sciences Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company is based in Vancouver, Canada.
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration with Tate & Lyle PLC (LSE:TATE) to broaden the scope of their joint sweetener development program to include multiple plant-based sweetener molecules. The expanded partnership builds on an...
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration with Tate & Lyle PLC (LSE:TATE) to broaden the scope of their joint sweetener development program to include multiple plant-based sweetener molecules. The expanded partnership builds on an...
Zaki Rakib: Thank you, Dory, and thank you all for joining us this morning. BioHarvest Sciences is an industrial plant cell culture biotech company and a leader in Botanical Synthesis, which is a patented non-GMO platform technology that industrializes what nature otherwise does slowly and produces high-value plant-derived compounds and botanical compositions without growing the plant itself. Using proprietary plant cell biology, elicitation technologies, AI-driven development and industrial scale bioreactors, BioHarvest creates highly consistent, bioavailable and patent-protected precision botanics or compounds possessing enhanced potency and purity compared to the original plant, along with the characteristics for commercial scalability.
Zaki Rakib: Thank you, Dory, and thank you all for joining us this morning. BioHarvest Sciences is an industrial plant cell culture biotech company and a leader in Botanical Synthesis, which is a patented non-GMO platform technology that industrializes what nature otherwise does slowly and produces high-value plant-derived compounds and botanical compositions without growing the plant itself. Using proprietary plant cell biology, elicitation technologies, AI-driven development and industrial scale bioreactors, BioHarvest creates highly consistent, bioavailable and patent-protected precision botanics or compounds possessing enhanced potency and purity compared to the original plant, along with the characteristics for commercial scalability.
Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in
The expanded collaboration builds on the initial agreement signed in 2024 and reflects strong technical progress to date, as well as Tate & Lyle's ambition to equip food and beverage manufacturers with a flexible
Moby summary of BioHarvest Sciences Inc. Common Stock's Q1 2026 earnings call
Moby summary of BioHarvest Sciences Inc. Common Stock's Q1 2026 earnings call
BioHarvest Sciences Inc (BHST) reports an 8% revenue increase and strategic advancements, despite facing higher net losses and operating expenses.
BioHarvest Sciences Inc (BHST) reports an 8% revenue increase and strategic advancements, despite facing higher net losses and operating expenses.
BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, plat
BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, plat
BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call May 14, 2026 8:00 AM EDTCompany ParticipantsZaki Rakib - Co-Founder, CEO, Executive Chairman &...
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness business. The company posted first quarter revenue of...
BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness business. The company posted first quarter revenue of...
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of +15.39% and +0.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of +15.39% and +0.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of AprilTwo-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 14, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE:...
BioHarvest Sciences (NASDAQ:BHST) affirms FY2026 sales outlook from $42.000 million-$48.000 million to $42.000 million-$48.000 million vs $44.721 million estimate.
BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 15.38 percent increase over losses of
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -0.12 | — | — |
| 2026-05-14 | -0.12 | -0.11 | +8.33% |
| 2026-03-31 | -0.10 | -0.10 | +4.76% |
| 2025-11-13 | -0.11 | -0.14 | -21.74% |
| 2025-08-11 | -0.11 | -0.24 | -123.26% |
| 2025-05-15 | -0.12 | -0.13 | -8.33% |
| 2025-03-31 | -0.12 | -0.17 | -37.84% |
| 2024-11-25 | -0.05 | -0.16 | -220.00% |
| 2024-08-29 | -0.10 | -0.04 | +60.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BHST | -7.66% | -12.27% | -25.63% | -38.37% |
| XLP | -1.50% | -5.50% | +6.73% | +0.10% |
| Alpha (stock − sector) | -6.16% | -6.77% | -32.36% | -38.46% |